LLY - ELI LILLY & Co
Close
797.48
1.480 0.186%
Share volume: 3,683,849
Last Updated: Mon 13 Jan 2025 10:00:00 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.28%
PREVIOUS CLOSE
CHG
CHG%
$796.00
-2.42
0.00%
Fundamental analysis
71%
Profitability
89%
Dept financing
25%
Liquidity
51%
Performance
70%
Performance
5 Days
-0.30%
1 Month
2.37%
3 Months
-14.20%
6 Months
-16.10%
1 Year
25.67%
2 Year
120.53%
Key data
Stock price
$797.48
DAY RANGE
$783.61 - $805.34
52 WEEK RANGE
$623.88 - $972.53
52 WEEK CHANGE
$25.67
DIVIDEND
$1.30
EX-DIVIDEND DATE
08/15/2024
NEXT EARNINGS DATE
N/A
Company detail
CEO: David A. Ricks
Region: US
Website: lilly.com
Employees: 39,000
IPO year: 1972
Issue type: Common Stock
Market: NYSE
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: lilly.com
Employees: 39,000
IPO year: 1972
Issue type: Common Stock
Market: NYSE
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic colorectal cancer, and hepatocellular carcinoma. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic ax
Recent news